Cartesian Therapeutics Q2 FY26 net income slips 0.74% to $15.8 million
RNAC•Cash position
Cash, cash equivalents and restricted cash totaled $149.3 million at June 30, 2026, expected to fund operations into 2028.
Quarterly results
Cartesian Therapeutics posted Q2 net income of $15.8 million, down 0.7% year over year; GAAP EPS slipped to $0.47 from $0.51.
R&D spending climbed 37% to $20.4 million; G&A rose 20.8% to $8.7 million.
Clinical program updates
Phase 3 AURORA trial in myasthenia gravis advanced, with data expected in 1Q27; BLA filing targeted for mid-2027.
WestGene in vivo MG Phase 1 trial is expected to start in 2H26 with data in 1H27; Phase 2 TRITON and pediatric HELIOS readouts are slated for 1H27.
